Tacalyx secured €11 million in a first closing of a seed extension round to advance TCX-201, an antibody-drug conjugate targeting an undisclosed tumor-associated carbohydrate antigen. The funding supports progression through preclinical development toward later-stage studies, as Tacalyx also selected TCX-201 as its first clinical candidate.